Next Article in Journal
miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy
Next Article in Special Issue
The p53 Pathway in Glioblastoma
Previous Article in Journal
RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact
Previous Article in Special Issue
The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53
Open AccessReview

p53 Isoforms and Their Implications in Cancer

Department of Cell and Molecular Biology, Uppsala University, Box-596, BMC, Uppsala SE-75124, Sweden
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(9), 288; https://doi.org/10.3390/cancers10090288
Received: 22 July 2018 / Revised: 18 August 2018 / Accepted: 18 August 2018 / Published: 25 August 2018
(This article belongs to the Special Issue p53 Signaling in Cancers)
In this review we focus on the major isoforms of the tumor-suppressor protein p53, dysfunction of which often leads to cancer. Mutations of the TP53 gene, particularly in the DNA binding domain, have been regarded as the main cause for p53 inactivation. However, recent reports demonstrating abundance of p53 isoforms, especially the N-terminally truncated ones, in the cancerous tissues suggest their involvement in carcinogenesis. These isoforms are ∆40p53, ∆133p53, and ∆160p53 (the names indicate their respective N-terminal truncation). Due to the lack of structural and functional characterizations the modes of action of the p53 isoforms are still unclear. Owing to the deletions in the functional domains, these isoforms can either be defective in DNA binding or more susceptive to altered ‘responsive elements’ than p53. Furthermore, they may exert a ‘dominant negative effect’ or induce more aggressive cancer by the ‘gain of function’. One possible mechanism of p53 inactivation can be through tetramerization with the ∆133p53 and ∆160p53 isoforms—both lacking part of the DNA binding domain. A recent report and unpublished data from our laboratory also suggest that these isoforms may inactivate p53 by fast aggregation—possibly due to ectopic overexpression. We further discuss the evolutionary significance of the p53 isoforms. View Full-Text
Keywords: p53; cancer; p53 isoform; ∆133p53; ∆160p53; ∆40p53; aggregation; prion p53; cancer; p53 isoform; ∆133p53; ∆160p53; ∆40p53; aggregation; prion
Show Figures

Graphical abstract

MDPI and ACS Style

Vieler, M.; Sanyal, S. p53 Isoforms and Their Implications in Cancer. Cancers 2018, 10, 288.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop